We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics

Product News   Apr 14, 2020

 
Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News

Advent has manufactured 13,000 doses of the novel COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222) for use in the Phase 2/3 clinical trial COV002 by the University of Oxford.

READ MORE

Thermo Fisher Scientific to Showcase New Mass Spectrometry Systems and Software at Virtual ASMS Event

Product News

Thermo Fisher Scientific will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its Orbitrap platform and expand research applications.

READ MORE

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

Like what you just read? You can find similar content on the communities below.

Diagnostics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE